News | Vascular Closure Devices | December 22, 2017

Enrollment Completed in U.S. IDE Trial for Manta Large Bore Vascular Closure Device

Device used to close punctures from 10F to 25F at femoral arterial access sites after percutaneous heart valve replacement procedures

Enrollment Completed in U.S. IDE Trial for Manta Large Bore Vascular Closure Device

December 22, 2017 — Essential Medical announced the completion of enrollment in the U.S. pivotal investigational device exemption (IDE) trial of the Manta large bore vascular closure device. The company said it has enrolled 341 patients at 21 different sites with 43 investigators in 10 months. Essential Medical President and CEO Greg Walters said the company expects to file a premarket approval (PMA) submission with the U.S. Food and Drug Administration (FDA) by the end of the first quarter in 2018.

Zvonimir Krajcer, M.D., the lead enroller and co-principal investigator in the MANTA trial, and co-director of the Peripheral Vascular Disease Service at Texas Heart Institute in Houston, stated, "I'm very encouraged by the results of the 31 Manta cases I personally performed and Dr. Strickman's 23 cases that I observed. At our site, we saw immediate hemostasis, patent vessels and reduced overall procedure time."

David Wood, M.D., co-principal investigator of the U.S. MANTA trial and a founding member of the Centre for Heart Valve Innovation in Vancouver, Canada, stated, "Beautiful device once you learn the nuances. John Webb and I deployed over 30 Manta devices at Vancouver General Hospital and St. Paul's Hospital and we are very encouraged by the results. It will be tough going back to our standard of care while we await commercial approval."

Manta is a novel CE Marked vascular closure device designed to close punctures ranging from 10F to 25F at femoral arterial access sites after percutaneous cardiac and peripheral catheterization procedures that use a large-bore device, such as transcatheter aortic valve implantation (TAVI), endovascular aneurysm repair (EVAR), ventricular assist device (VAD) implantation and balloon aortic valvuloplasty (BAV). Manta is an investigational device in the United States and Canada and is not yet commercially available.

These procedures are the fastest growing segment of the cardiovascular market, according to Essential Medical, and are driving the potential worldwide market for large bore vascular closure devices to exceed $600 million within five years. Closure of large bore femoral access sites has been associated with significant morbidity including long times to achieve hemostasis, extended procedure time, need for a vascular surgeon in the catheterization lab, delayed ambulation, higher rate of complications and higher total cost of care. Manta was designed to address the complexities of closing these large punctures in high-pressure vessels utilizing novel closure technology. The device is intended to provide reliable and repeatable deployment with immediate hemostasis in order to reduce complications associated with large bore closure.

Manta is CE marked and currently available for sale in the Netherlands, Norway, Finland, Denmark and Sweden.

For more information: www.essmedclosure.com

Related Content

TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
htisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...